Andrea Rubboli

Dr. Andrea Rubboli


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Heart Journal
Verified
Journal Article
Closed access
CVChristiaan Vrints
Christiaan Vrints
FAFelicita Andreotti
Felicita Andreotti
KKKonstantinos C Koskinas
Konstantinos C Koskinas
XRXavier Rossello
Xavier Rossello
MAMarianna Adamo
Marianna Adamo
ASAleksandr Borisovich Shek
Aleksandr Borisovich Shek

1 January 2008 in Annals of Medicine
Verified
Journal Article
Closed access
ARAndrea Rubboli
Andrea Rubboli
JHJonathan L. Halperin
Jonathan L. Halperin
JAJuhani Airaksinen
Juhani Airaksinen
MBMichael Buerke
Michael Buerke
EEEric Eeckhout
Eric Eeckhout
GLGregory Y. H. Lip
Gregory Y. H. Lip
Dual antiplatelet treatment with aspirin and clopidogrel is recommended after coronary stenting (PCI-S). There is scant evidence defining optimal post-PCI-S antithrombotic therapy in patients with atrial fibrillation (AF) in whom oral anticoagulation (OAC) is mandated. To evaluate the safety and efficacy of the antithrombotic strategies for this population, we conducted a systematic review of the available evidence in patients treated with OAC undergoing PCI-S. AF was the most frequent indication for OAC. Post-PCI-S management was highly variable, and triple therapy with warfarin, aspirin, and clopidogrel was the most frequent and effective combination. Warfarin plus aspirin alone was not sufficiently effective in the early period after PCI-S and should not be prescribed. While acknowledging that the optimal antithrombotic treatment for patients with AF at medium or high thromboembolic risk undergoing PCI-S is currently undefined, triple therapy of warfarin, aspirin, and clopidogrel is currently recommended, although associated with an increased risk of major bleeding. Restrictive use of drug-eluting stent is also recommended, due to the need for prolonged multiple-drug antithrombotic therapy which may increase the bleeding risk. Whether the combination of warfarin and clopidogrel (without aspirin) will preserve efficacy and produce less bleeding is an important issue still needing to be addressed.

30 January 2014 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
ARAndrea Rubboli
Andrea Rubboli
ASAxel Schlitt
Axel Schlitt
TKTuomas Kiviniemi
Tuomas Kiviniemi
Fausto BiancariFausto Biancari
Fausto Biancari
PKPasi P. Karjalainen
Pasi P. Karjalainen
FGfor the AFCAS Study Group
for the AFCAS Study Group

1 January 2011 in World Journal of Cardiology
Verified
Journal Article
Open access
ARAndrea Rubboli
Andrea Rubboli
CBCecilia Becattini
Cecilia Becattini
FVFreek Wa Verheugt
Freek Wa Verheugt
Bleeding is the most important complication of oral anticoagulation (OAC) with vitamin K-antagonists. Whilst bleeding is unavoidably related to OAC, it may have a great impact on the prognosis of treated subjects by leading to discontinuation of treatment, permanent disability or death. The yearly incidence of bleeding during OAC is 2%-5% for major bleeding, 0.5%-1% for fatal bleeding, and 0.2%-0.4% for intracranial bleeding. While OAC interruption and/or antagonism, as well as administration of coagulation factors, represent the necessary measures for the management of bleeding, proper stratification of the individual risk of bleeding prior to start OAC is of paramount importance. Several factors, including advanced age, female gender, poor control and higher intensity of OAC, associated diseases and medications, as well as genetic factors, have been proven to be associated with an increased risk of bleeding. Most of these factors have been included in the development of bleeding prediction scores, which should now be used by clinicians when prescribing and monitoring OAC. Owing to the many limitations of OAC, including a narrow therapeutic window, cumbersome management, and wide inter- and intra-individual variability, novel oral anticoagulants, such as factor Xa inhibitors and direct thrombin inhibitors, have been recently developed. These agents can be given in fixed doses, have little interaction with foods and drugs, and do not require regular monitoring of anticoagulation. While the novel oral anticoagulants show promise for effective thromboprophylaxis in atrial fibrillation and venous thromboembolism, definitive data on their safety and efficacy are awaited.

1 August 2005 in Cardiology
Verified
Journal Article
Closed access
ARAndrea Rubboli
Andrea Rubboli
MMMilena Milandri
Milena Milandri
CCCristina Castelvetri
Cristina Castelvetri
BCBenilde Cosmi
Benilde Cosmi
The combination of oral anticoagulation (OAC) and aspirin was the antithrombotic treatment initially adopted after coronary stenting (PCI-S). Although dual antiplatelet therapy with aspirin and a thienopyridine subsequently proved safer and more effective, OAC and aspirin combination is still used in patients with an indication for long-term OAC undergoing PCI-S. The absolute (AR) and relative (RR) risk of cardiac events and hemorrhagic/vascular complications of OAC and aspirin versus antiplatelet therapy were evaluated in a meta-analysis of four historical clinical trials. In 2,436 patients, the RR of a 30-day primary composite endpoint of death, myocardial infarction and the need for revascularization was significantly reduced by antiplatelet therapy (RR 0.41; 95% CI 0.25–0.69), whereas the RR of stent thrombosis (RR 0.26; 95% CI 0.06–1.14) and major bleeding (RR 0.36; 95% CI 0.14–1.02) was not statistically different. The 30-day AR of death, myocardial infarction, need for revascularization, major bleedings and vascular complications with OAC and aspirin were 0.65, 3.8, 4.2, 6.4 and 6.6%, respectively. In conclusion, due to the low AR of adverse events, the combination of OAC and aspirin appears an acceptable treatment after PCI-S in patients in whom long-term OAC is deemed mandatory.

1 April 2014 in Thrombosis Research
Verified
Journal Article
Closed access
MPMarja K. Puurunen
Marja K. Puurunen
TKTuomas Kiviniemi
Tuomas Kiviniemi
ASAxel Schlitt
Axel Schlitt
ARAndrea Rubboli
Andrea Rubboli
BDBritta Dietrich
Britta Dietrich
JAJuhani Airaksinen
Juhani Airaksinen